MetaCap

Xenetic Biosciences (XBIO) vs XTL Biopharmaceuticals (XTLB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.

Summary

Xenetic Biosciences is the larger company by market cap ($5.2 million vs $4.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Head-to-head

XBIO versus XTLB key metrics
MetricXBIOXTLB
Share price$2.21$1.98
Market cap$5.18M$4.87M
1-day change+2.55%-1.98%
EPS (TTM)$-1.18$-0.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$10.24$7.44
52-week low$1.87$1.98
Distance from 52-week high-78.42%-73.39%
Average volume88.85K8.18K
Shares outstanding2.34M2.46M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

XBIO vs XTLB FAQ

Which is bigger, Xenetic Biosciences or XTL Biopharmaceuticals?

Xenetic Biosciences (XBIO) is larger, with a market capitalization of $5.18M compared with $4.87M for XTL Biopharmaceuticals (XTLB).

Are Xenetic Biosciences and XTL Biopharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons